Other Income & Expense

Equity Method Income

Over 2 years (FY 2021 to FY 2024), Equity Method Income shows a downward trend with a -100.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionOther Income & Expense
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026

How to read this metric

An increase reflects strong performance from joint ventures or strategic partners, while a decrease indicates underperformance in those specific investments.

Detailed definition

This metric captures the company's proportionate share of the net earnings or losses from investments in unconsolidated...

Peer comparison

Common in technology and manufacturing sectors where joint ventures are used for R&D or supply chain integration.

Metric ID: equity_method_income

Historical Data

13 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24
Value$34.30M$1.10M$17.70M-$3.30M$5.90M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
QoQ Change-96.8%>999%-118.6%+278.8%-100.0%
YoY Change-82.8%+100.0%-100.0%
Range-$3.30M$34.30M
CAGR-100.0%
Avg YoY Growth-27.6%
Median YoY Growth-82.8%

Product Breakdown

View all
SegmentQ2 '21Q3 '21Q4 '21Q1 '22Q3 '22
ADUHELM$45.00M$45.00M$45.00M$59.00M$41.00M
Total$34.30M$1.10M$17.70M-$3.30M

Equity Method Income at Other Companies

Frequently Asked Questions

What is Biogen's equity method income?
Biogen (BIIB) reported equity method income of $0.00 in Q4 2024.
What is the long-term trend for Biogen's equity method income?
Over 2 years (2021 to 2024), Biogen's equity method income has grown at a -100.0% compound annual growth rate (CAGR), from $34.90M to $0.00.
What does equity method income mean?
The company's share of profits or losses from businesses it partially owns.